BioSpace News Archive

Dyadic International, Inc. today announced that its Chief Executive Officer, Mark Emalfarb will be participating in the following two upcoming conferences.

Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that fourth quarter and full year 2022 financial results will be released on Thursday, February 16, 2023 after the market closes.

Oligomerix, Inc. today announced the dosing of its first subjects in the company’s Phase 1a clinical trial evaluating lead candidate OLX-07010.

Athersys, Inc. (NASDAQ: ATHX) , a cell therapy and regenerative medicine company developing MultiStem ® (invimestrocel) for critical care indications, announced today it will host a business update conference call on February 14, 2023 at 11:00 a.m. Eastern Time.

The National Center for Child Health and Development (NCCHD), Japan, and OmniTier Inc., USA, working collaboratively have demonstrated notably improved diagnostics rates for rare disease diagnostics.

Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2022 fourth quarter and full year ended December 31, 2022 on Friday, March 3, 2023 before the open of the U.S. financial markets.

Frontera Therapeutics, a global clinical-stage biotechnology company that seeks to develop novel and best-in-class gene therapy medicines to improve the lives of patients across multiple disease areas, announced that it has dosed the first patient in a clinical trial of its innovative gene therapy product, FT-003, at the Ophthalmology Hospital of Tianjin Medical University in Tianjin, China.

ObvioHealth and Sterling IRB today announce a partnership to help speed access and adoption of decentralized clinical trials.

Amgen (NASDAQ:AMGN) and AstraZeneca today announced the U.S. Food and Drug Administration (FDA) has approved TEZSPIRE® (tezepelumab-ekko) for self-administration in a pre-filled, single-use pen for patients aged 12 years and older with severe asthma.

The Center for Breakthrough Medicines, a contract development, and manufacturing organization, has launched its plasmid manufacturing offering, Precision Plasmids™ to provide phase-appropriate plasmid on-demand for any company seeking to accelerate their path to clinic for cell and gene therapies.